<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603720</url>
  </required_header>
  <id_info>
    <org_study_id>AG0086</org_study_id>
    <secondary_id>5R01AG015466-08</secondary_id>
    <secondary_id>05-0810</secondary_id>
    <secondary_id>RDRC# 482F</secondary_id>
    <secondary_id>GCRC# 1002</secondary_id>
    <nct_id>NCT00603720</nct_id>
  </id_info>
  <brief_title>Role of Nitric Oxide in the Impact of Aging on Myocardial Remodeling</brief_title>
  <official_title>PET Detection of the Effects of Aging on the Human Heart. Aim#1-Impact of Aging on Myocardial Remodeling: Role of Nitric Oxide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine, with Positron Emission Tomography (PET), the role
      of nitric oxide in the age-associated effect on fatty acid and glucose delivery on myocardial
      substrate metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aging is associated with an increased incidence and severity of various cardiovascular
      disorders. Previously, our laboratory has demonstrated an age-related shift in the substrates
      used by the heart for metabolism from primarily fatty acids to primarily glucose.
      Furthermore, other institutions have demonstrated that a similar shift can be induced, in
      animal models, with specific nitric oxide synthase inhibitors, such as L-NAME
      (N-Nitro-L-Arginine Methyl Ester). Our hypothesis is that a reduction in nitric oxide (NO)
      synthesis is responsible for the age-related shift in heart function. Accordingly, we aim to
      demonstrate, in young patients, an acute, transient shift in substrate use from fatty acids
      to glucose with L-NMMA (citrate) in association with depressed heart function. Also, we aim
      to demonstrate in the elderly an acute, transient shift in substrate use from glucose to
      fatty acids with L-arginine, in association with improved cardiac function. These results
      will demonstrate a portion of the mechanism for the age-related shift in substrate
      utilization.

      Each participant will undergo a screening visit which will include a Glucose Tolerance Test,
      an echocardiogram in conjunction with a treadmill stress test to exclude cardiac disease, and
      baseline blood work. Then each patient will have 3 PET study days, each lasting about 5-6
      hours. During this time, the patient will have two IVs (one in each arm). They will have 4
      injections of different radioactive isotopes (015 Water, C11 Acetate, C11 Glucose, and C11
      Palmitate). After each injection, about 8-10 blood samples will be drawn over the course of
      about ½ to 1 hour of time. In between each injection, there will be about an hour break for
      the patient to rest and move around. During one of the breaks, the patient will have another
      echocardiogram. On the day 2 and 3 PET, the patient will have a 30-60 minute infusion of
      L-NAME. Then the PET study will commence. After the study is over the participant will have a
      10-minute infusion of L-arginine to reverse the effects of L-NAME.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of NO Inhibition on Myocardial Substrate Metabolism in Humans</measure>
    <time_frame>1-3 months</time_frame>
    <description>Determine in young healthy volunteers the extent to which acute inhibition of nitric oxide production will effect a shift in myocardial substrate utilization characterized as a decline in myocardial fatty acid oxidation, and perhaps myocardial fatty acid utilization, and increase in myocardial glucose uptake, and whether these changes are associated with a decline in LV function.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>L-Name in Young</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 individuals age 18-35 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 individuals age 18-35 will be getting an infusion of phenylephrine (primarily an alpha agonist) during 3 separate PET study days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-arginine in Young</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 individuals age 18-35 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-arginine in Old</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 individuals age 60-75 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-NAME in Old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 individuals age 60-75 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-NAME</intervention_name>
    <description>nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging</description>
    <arm_group_label>L-NAME in Old</arm_group_label>
    <arm_group_label>L-Name in Young</arm_group_label>
    <other_name>N (G)-nitro-L- arginine methyl ester</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Arginine</intervention_name>
    <description>aids in nitric oxide production</description>
    <arm_group_label>L-arginine in Old</arm_group_label>
    <arm_group_label>L-arginine in Young</arm_group_label>
    <other_name>2-Amino-5-guanidinopentanoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>alpha agonist; 10 μg/kg/min infusion during PET study</description>
    <arm_group_label>Phenylephrine</arm_group_label>
    <other_name>(R)-3-[-1-hydroxy-2-(methylamino)ethyl]phenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 18-35 or 60-75

          -  Normal glucose tolerance test

          -  Normal plasma fasting lipid panel (fasting total cholesterol less than 220 mg/dL)

          -  Normal rest/stress echocardiogram

          -  BMI (Body Mass Index) less than 30 kg/m2

        Exclusion Criteria:

          -  Coronary artery disease

          -  High blood pressure

          -  Current smoker

          -  Diabetes mellitus

          -  Cardiovascular disease (signs and symptoms of any kind)

          -  History of stroke, peripheral vascular disease, or arrhythmia

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Gropler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ogawa T, Spina RJ, Martin WH 3rd, Kohrt WM, Schechtman KB, Holloszy JO, Ehsani AA. Effects of aging, sex, and physical training on cardiovascular responses to exercise. Circulation. 1992 Aug;86(2):494-503.</citation>
    <PMID>1638717</PMID>
  </reference>
  <reference>
    <citation>Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res. 1991 Jun;68(6):1560-8.</citation>
    <PMID>2036710</PMID>
  </reference>
  <reference>
    <citation>Coughlin SS, Neaton JD, Sengupta A, Kuller LH. Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1994 Jan 15;139(2):166-72.</citation>
    <PMID>8296783</PMID>
  </reference>
  <reference>
    <citation>Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999 Feb;137(2):352-60.</citation>
    <PMID>9924171</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <results_first_submitted>February 6, 2018</results_first_submitted>
  <results_first_submitted_qc>September 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 12, 2018</results_first_posted>
  <last_update_submitted>September 11, 2018</last_update_submitted>
  <last_update_submitted_qc>September 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET</keyword>
  <keyword>Heart metabolism</keyword>
  <keyword>Nitric oxide</keyword>
  <keyword>Myocardial remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>NG-Nitroarginine Methyl Ester</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>L-Name in Young</title>
          <description>20 individuals age 18-35 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME.
L-NAME: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging</description>
        </group>
        <group group_id="P2">
          <title>Phenylephrine</title>
          <description>25 individuals age 18-35 will be getting an infusion of phenylephrine (primarily an alpha agonist) during 3 separate PET study days
Phenylephrine: alpha agonist; 10 μg/kg/min infusion during PET study</description>
        </group>
        <group group_id="P3">
          <title>L-arginine in Young</title>
          <description>20 individuals age 18-35 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
L-Arginine: aids in nitric oxide production</description>
        </group>
        <group group_id="P4">
          <title>L-arginine in Old</title>
          <description>20 individuals age 60-75 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
L-Arginine: aids in nitric oxide production</description>
        </group>
        <group group_id="P5">
          <title>L-NAME in Old</title>
          <description>20 individuals age 60-75 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME
L-NAME: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>L-Name in Young</title>
          <description>20 individuals age 18-35 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME.
L-NAME: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging</description>
        </group>
        <group group_id="B2">
          <title>Phenylephrine</title>
          <description>25 individuals age 18-35 will be getting an infusion of phenylephrine (primarily an alpha agonist) during 3 separate PET study days
Phenylephrine: alpha agonist; 10 μg/kg/min infusion during PET study</description>
        </group>
        <group group_id="B3">
          <title>L-arginine in Young</title>
          <description>20 individuals age 18-35 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
L-Arginine: aids in nitric oxide production</description>
        </group>
        <group group_id="B4">
          <title>L-arginine in Old</title>
          <description>20 individuals age 60-75 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
L-Arginine: aids in nitric oxide production</description>
        </group>
        <group group_id="B5">
          <title>L-NAME in Old</title>
          <description>20 individuals age 60-75 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME
L-NAME: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of NO Inhibition on Myocardial Substrate Metabolism in Humans</title>
        <description>Determine in young healthy volunteers the extent to which acute inhibition of nitric oxide production will effect a shift in myocardial substrate utilization characterized as a decline in myocardial fatty acid oxidation, and perhaps myocardial fatty acid utilization, and increase in myocardial glucose uptake, and whether these changes are associated with a decline in LV function.</description>
        <time_frame>1-3 months</time_frame>
        <population>PI left institution. Efforts were made to access the data, without success so there is no access to the data.</population>
        <group_list>
          <group group_id="O1">
            <title>L-Name in Young</title>
            <description>20 individuals age 18-35 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME.
L-NAME: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging</description>
          </group>
          <group group_id="O2">
            <title>Phenylephrine</title>
            <description>25 individuals age 18-35 will be getting an infusion of phenylephrine (primarily an alpha agonist) during 3 separate PET study days
Phenylephrine: alpha agonist; 10 μg/kg/min infusion during PET study</description>
          </group>
          <group group_id="O3">
            <title>L-arginine in Young</title>
            <description>20 individuals age 18-35 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
L-Arginine: aids in nitric oxide production</description>
          </group>
          <group group_id="O4">
            <title>L-arginine in Old</title>
            <description>20 individuals age 60-75 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
L-Arginine: aids in nitric oxide production</description>
          </group>
          <group group_id="O5">
            <title>L-NAME in Old</title>
            <description>20 individuals age 60-75 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME
L-NAME: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of NO Inhibition on Myocardial Substrate Metabolism in Humans</title>
          <description>Determine in young healthy volunteers the extent to which acute inhibition of nitric oxide production will effect a shift in myocardial substrate utilization characterized as a decline in myocardial fatty acid oxidation, and perhaps myocardial fatty acid utilization, and increase in myocardial glucose uptake, and whether these changes are associated with a decline in LV function.</description>
          <population>PI left institution. Efforts were made to access the data, without success so there is no access to the data.</population>
          <units>percentage of substrate</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">PI left institution. There is no access to the data.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">PI left institution. There is no access to the data.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">PI left institution. There is no access to the data.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">PI left institution. There is no access to the data.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">PI left institution. There is no access to the data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 to 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>L-Name in Young</title>
          <description>10 individuals age 18-35 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME.
L-NAME: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging</description>
        </group>
        <group group_id="E2">
          <title>Phenylephrine</title>
          <description>10 individuals age 18-35 will be getting an infusion of phenylephrine (primarily an alpha agonist) during 3 separate PET study days
Phenylephrine: alpha agonist; 10 μg/kg/min infusion during PET study</description>
        </group>
        <group group_id="E3">
          <title>L-arginine in Young</title>
          <description>12 individuals age 18-35 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
L-Arginine: aids in nitric oxide production</description>
        </group>
        <group group_id="E4">
          <title>L-arginine in Old</title>
          <description>12 individuals age 60-75 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
L-Arginine: aids in nitric oxide production</description>
        </group>
        <group group_id="E5">
          <title>L-NAME in Old</title>
          <description>10 individuals age 60-75 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME
L-NAME: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations or caveats</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Gropler, MD, Chief of Cardiovascular Imaging Laboratory</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-747-3877</phone>
      <email>groplerr@mir.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

